Loading...
•
Dec 31, 2024
Cellectis SA Q1 2025 Earnings Report
Cellectis SA reported narrowed net loss in Q4 2024 with continued investment in trait development and strategic cost-saving initiatives.
Key Takeaways
Cellectis (Cibus) achieved revenue growth in Q4 2024 while significantly reducing net loss compared to the prior year. Operational focus included commercialization progress, expanded strategic collaborations, and cost-cutting measures to extend cash runway.
Revenue for Q4 2024 was $1,212,000, up from $1,103,000 in Q4 2023
Net loss decreased significantly to $25,804,000 from $277,208,000
Cash and cash equivalents stood at $14,433,000 at year-end, before January 2025 offering
Operating expenses dropped with no goodwill impairment charges this quarter
Cellectis SA
Cellectis SA
Forward Guidance
Cellectis (Cibus) aims to progress its commercial and regulatory efforts in gene editing and sustainable ingredients through 2025 while pursuing strategic alternatives.
Positive Outlook
- Filed field research proposal for gene-edited rice in California
- Advanced regulatory support for gene editing in the EU
- Achieved strategic partnerships for rice and canola trait commercialization
- Announced breakthrough edits in soybean HT2 platform
- Secured $22.6 million gross from January 2025 offering
Challenges Ahead
- Continued operating losses driven by R&D and SG&A expenses
- Ongoing royalty liability interest expense of $8.2 million
- Cash runway limited to late Q3 2025 without further financing
- Net loss remained high despite goodwill impairment absence
- High dependency on successful commercialization to generate revenue